Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

Series of PDE5 inhibitors identified by Pfizer researchers

Nov. 21, 2002

Selective p38alpha MAPK inhibitor NPC-31145 improves outcome in glomerulonephritis

Nov. 19, 2002

First approval obtained for Cialis

Nov. 15, 2002

Novel substance P antagonists covered by Takeda patent

Nov. 15, 2002

New 5-HT2C agonists for erectile dysfunction and other disorders under study at Yamanouchi

Nov. 15, 2002

Accelerated approval plan for KRX-101

Nov. 14, 2002

Positive results from TA-1790 erectile dysfunction study

Nov. 13, 2002

Health Canada approves irbesartan for diabetic renal disease

Nov. 13, 2002

New PDE5 inhibitors in early development at Pfizer

Nov. 13, 2002

Series of PDE5 inhibitors in early development at Tanabe Seiyaku

Nov. 11, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....